Whitehawk Therapeutics, Inc. (WHWK) Form 8-K — Nov 9, 2026
Whitehawk Therapeutics reported Q3 2026 results with a net loss of $21.2 million versus $17.7 million a year ago, and R&D expense rising to $18.1 million from $14.3 million as its clinical pipeline expands. The company held $169.7 million in cash and short-term investments at quarter-end, which it expects to fund operations into the second half of 2028. Operationally, Whitehawk initiated a U.S. Phase 1 trial of HWK-206, its third ADC program to enter the clinic in 12 months, and received FDA Fast Track designation for the asset in small-cell lung cancer.
Key figures
- Revenue
- 0
- Total Assets
- 173686000
- Cash Position
- 169700000
- Runway
- funded into 2H 2028
- Cash dec 31 2025
- 145700000
- Rnd expense q3 2025
- 14345000
- Rnd expense q3 2026
- 18138000
- Weighted avg shares q3 2026
- 93866642
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.